Program: Oral and Poster Abstracts
Session: 902. Health Services and Outcomes Research – Malignant Diseases: Poster III
Methods: Using data from 18 SEER registries, we examined differences in incidence, mortality and survival from 1973-2012 for 89,867 myeloma patients (68,701 white, 16,364 black and 4,802 others) by race, gender and age-stratification. ICD-O-3 and morphologic (9732/3) codes were used to identify cases. Age-adjusted incidence and mortality rates, regression analysis and survival curves were calculated by race. Statistics were computed using the National Cancer Institute SEER*Stat software, version 8.2.0. and SAS software, version 9.4 (SAS Institute Inc, Cary, NC).
Results: Median age at diagnosis was 70 years (range 20-100 years) for the overall population (blacks: 66 years; whites: 71 years, and others: 69 years (P<0.01). The age-adjusted incidence rates per 100,000 populations were: blacks- 11.9 (95% CI 11.6, 12.1, P-value<0.05); whites- 5.1 (95% CI 5.0, 5.2) and others- 3.7 (95% CI 3.6, 3.9). The incidence rates were higher for black males, 14.2 (95% CI 14, 14.7) followed by black females, 10.3 (95% CI 10, 10.6, P-value<0.05). Using white male as reference, incidence rate ratios for black males and females are 2.20 (95% CI 2.12, 2.28) and 1.60 (95% CI 1.54, 1.65) respectively. The 2-year relative survival rates (RSR) for the study population were: whites- 60.4%, blacks: 64.1% and others: 68.4%, respectively. The 5-year RSR by race and gender are included in figure 1. On the survival analysis, black race is an independent factor to have improved survival (HR=0.884, P-value<0.0001). This was corroborated on regression analysis, showing decreased hazard ratios for blacks (HR 0.856 95% CI 0.834, 0.878) compared to whites (P-value<0.001).
Conclusions: Black patients are diagnosed younger than whites and other races. The IRRs for black males are twice compared to white males. While the 5-year RSRs are improving for all races and genders, black race is an independent factor to have improved survival. Further population-based studies focused on the exploring the underlying biological mechanisms of disease may explain the earlier presentation with disease and better overall survival among black patients.
Disclosures: Lonial: Janssen: Consultancy , Research Funding ; Celgene: Consultancy , Research Funding ; Millennium: Consultancy , Research Funding ; Onyx: Consultancy , Research Funding ; Bristol-Myers Squibb: Consultancy , Research Funding ; Novartis: Consultancy , Research Funding . Nooka: Onyx Pharmaceuticals: Consultancy ; Spectrum Pharmaceuticals: Consultancy .
See more of: Health Services and Outcomes Research – Malignant Diseases
See more of: Oral and Poster Abstracts
*signifies non-member of ASH